Gilead 2Q Revenues: $6.2 billion (+21%) 2Q Earnings: $1.5 billion (loss of $3.3 billion 2Q20) Comments: Growth in the quarter was primarily due to Veklury (remdesivir), with sales of $829 million, higher demand for Biktarvy and hepatitis C virus (HCV) products, and continued uptake in the U.S. of Trodelvy and Tecartus. Product sales excluding Veklury increased 5% to $5.3 billion in the quarter, offset by loss of exclusivity of Truvada and Atripla in the U.S. with sales down 72% to $108 mil...